Related Experiment Videos
Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose
M A Perazella1, R L Mahnensmith
1Department of Medicine, Yale University School of Medicine, New Haven, CT 06520-8029, USA.
Abstract:
Trimethoprim-sulfamethoxazole is a frequently prescribed antibiotic with a wide spectrum of antimicrobial activity. As a result of the increasing number of AIDS patients requiring therapy for Pneumocystis carinii pneumonia, high dose trimethoprim-sulfamethoxazole use had dramatically increased. A previously unreported and potentially lethal adverse reaction associated with high dose trimethoprim-sulfamethoxazole therapy, hyperkalemia, subsequently developed. Recognition of this potassium disorder led to investigation and description of the mechanism by which trimethoprim-sulfamethoxazole induced hyperkalemia. Trimethoprim was found to act like the potassium-sparing diuretic amiloride and reduce renal potassium excretion. Subsequent to this work, a handful of cases noted the development of hyperkalemia with standard dose trimethoprim-sulfamethoxazole in elderly patients without evidence of an obvious defect in potassium homeostasis. A prospective surveillance study of patients treated with standard dose trimethoprim-sulfamethoxazole as compared to similar controls treated with other antibiotics confirmed the rise in potassium concentration associated with trimethoprim-sulfamethoxazole therapy. Patients with mild renal insufficiency were the only group at significant risk for more severe hyperkalemia. Hence, trimethoprim-sulfamethoxazole therapy can be complicated by hyperkalemia regardless of the dose employed.
Insights
Trimethoprim-sulfamethoxazole can cause dangerous hyperkalemia, a potassium disorder. This risk exists with both high and standard doses, especially in patients with kidney issues.
Area of Science:
- Pharmacology
- Nephrology
- Infectious Diseases
Background:
- Trimethoprim-sulfamethoxazole is a widely used antibiotic.
- Increased use in AIDS patients for Pneumocystis carinii pneumonia led to higher doses.
- Hyperkalemia, a serious adverse reaction, was observed with high-dose therapy.
Purpose of the Study:
- To investigate the mechanism of trimethoprim-sulfamethoxazole-induced hyperkalemia.
- To determine if standard doses also cause hyperkalemia, particularly in vulnerable populations.
- To assess the risk of hyperkalemia in patients with renal insufficiency.
Main Methods:
- Investigated the mechanism of trimethoprim's effect on renal potassium excretion.
- Observed cases of hyperkalemia with standard-dose trimethoprim-sulfamethoxazole in elderly patients.
- Conducted a prospective surveillance study comparing trimethoprim-sulfamethoxazole to other antibiotics.
Main Results:
- Trimethoprim was found to inhibit renal potassium excretion, similar to amiloride.
- Hyperkalemia occurred with standard-dose trimethoprim-sulfamethoxazole, especially in the elderly.
- A significant increase in potassium concentration was confirmed with trimethoprim-sulfamethoxazole therapy.
- Patients with mild renal insufficiency were at higher risk for severe hyperkalemia.
Conclusions:
- Trimethoprim-sulfamethoxazole therapy is associated with hyperkalemia regardless of dose.
- The risk is elevated in patients with mild renal insufficiency.
- Clinicians should monitor potassium levels during trimethoprim-sulfamethoxazole treatment, particularly in at-risk patients.